This report is an essential tool for understanding the size and growth opportunity in molecular POC. Molecular point of care (mPOC) has gone from novel trend to significant contributor to the market. The instruments sold by Abbott, BioMérieux, Cepheid and increasingly, a host of other companies, are a significant contributor to the IVD POC market. Knowing these markets is essential to knowing the opportunity in point of care testing and microbiology IVD.
Since 2013, Kalorama has been producing a dedicated report on systems and consumables. The Market and Future Potential for Molecular Point of Care (POC), 2023 is Kalorama’s latest. The report provides market sizing, forecasting, trend mapping and competitive analysis for point of care tests using PCR or other molecular technology with fast turnaround times and usability in near-patient settings.
Kalorama reports provide real-world analysis and model for relevant circumstances. As an example, analysts provide two different market perspectives. Near patient molecular testing using small instruments, and molecular point-of-care. Both markets are provided so the report can be useful for any business plans. As far as we know, Kalorama is the only market research resource providing this insight.
The data in The Market and Future Potential for Molecular Point of Care (POC), 2023 includes information on systems and competitor analysis, as well as data on the size and growth of the market:
What are the mPOC market opportunities beyond COVID-19?
What are the current systems on the market? Who’s winning?
What’s the size of the Molecular Point of Care Market: 2022-2027
Geographic Breakout of the Molecular Point of Care Market, 2021 (N. America, Europe, APAC, RoW)
Segment Breakout of Molecular Point of Care Market, 2022 (Respiratory vs. Other)
Breakout of mPOC Respiratory, 2022 (%; Flu, Strep, RSV, Other)
Near Patient Molecular IVD Market: 2022-2027
Near Patient Molecular Market Share by Vendor, 2022
Molecular Point of Care Market Share by Vendor, 2022
Company Profiles
Many trends are covered in the report, including the role of COVID-19 testing, menu expansion, disease statistics, the COVID-19 crisis, immunoassay competition and enhancement of those competitive POC systems, emerging markets, new journal studies about the efficacy of mPOC, and other trends.
Market Share
The report contains market share for both the molecular and the near-term market
Companies covered in this report, in profiles and/or product tables and market developments discussion include:
Abbott Laboratories
Aidian Oy
Akonni Biosystems
Anitoa
binx health, inc.
Biocartis NV
BioGX
bioMérieux SA
Cepheid
Credo Bioscience
Cue Health
Curetis NV
Curiosity Diagnostics (Bio-Rad)
DiaSorin S.p.A
Domus Diagnostics
Fluxergy
GenMark Diagnostics
Genomadix
Greiner Bio-One GmbH
LEX Diagnostics
Meridian Bioscience, Inc.
Mesa Biotech, Inc.
MicroGEM
Minute Molecular
Nanopath
QIAGEN NV
QuantuMDx Group
Quidel Corporation
Roche
Rover Diagnostics
Sekisui Diagnostics LLC
T2 Biosystems
Table of Contents
Chapter 1: Executive Summary
Figure 1-1: Molecular Point of Care Market, 2022-2026 ($M)
Figure 1-2: Near Patient Molecular Systems Market: 2022-2027 ($M)
Where is Molecular Point of Care in 2023?
Table 1-1: Molecular Point of Care Market, 2022-2027 ($M)
Molecular Point of Care Market Analysis
Table 1-2: Molecular Point of Care Market, 2022-2027 (%)
Table 2-2: Deals in Molecular Point of Care, April 2019-January 2023
Advantages and Disadvantages of Molecular Point of Care
Table 2-3: Disadvantages of Molecular Point of Care, by Setting (Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC)
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
Mesa Biotech Strep A Approval
Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Thermo Acquires Mesa Biotech
EU Researchers Awarded €3M to Develop POC Molecular Tests
Scope Fluidics AST System Sees Investment
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Line Probe Assays
Next-Generation Sequencing
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics
Influenza
Reclassification of RIDTs
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
Emerging Applications
Zika
Other Respiratory Infections
Group B Streptococcus
Human Papillomavirus
Herpes Simplex Virus
Vaginitis
Tuberculosis
Malaria
Other Tropical and Neglected Diseases
Cancer
European Device Regulations Nearing
Chapter 3: Market Analysis
Molecular Point of Care Market Analysis
Table 3-1: Molecular Point of Care Market, 2022-2027 ($M, %)
Figure 3-1: Molecular Point of Care Market, 2022-2026 ($M)
Table 3-2: Molecular Point of Care Market Share, by Vendor (Abbott, bioMérieux, Cepheid, Cue Health, Roche, Other), 2022 ($M, %)
Figure 3-2: Molecular Point of Care Market Share, by Vendor (Abbott, bioMérieux, Cepheid, Cue Health, Roche, Other), 2022 (%)
Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2022 (N. America, Europe, APAC, RoW)
Table 3-4: Segment Breakout of Molecular Point of Care Market, 2022 (COVID-Respiratory vs. Other)
Figure 3-3: Breakout of Molecular Point of Care Market (Respiratory, Other), 2022 (%)
“Near Patient Molecular” Market
Table 3-5: Near Patient Molecular Systems Market, 2022-2027
